Literature DB >> 1657451

Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reperfusion.

M Hori1, M Kitakaze, H Sato, S Takashima, K Iwakura, M Inoue, A Kitabatake, T Kamada.   

Abstract

BACKGROUND: Acidosis during early reperfusion is reported to be beneficial for myocardial stunning. We tested in 31 dogs the hypothesis that staged reperfusion is beneficial to myocardial stunning. METHODS AND
RESULTS: Contractile dysfunction was observed 3 hours after the onset of reperfusion after 15 minutes of occlusion of the coronary artery. In the staged reperfusion, pH of the coronary venous blood was lower for 20 minutes and fractional shortening was significantly improved compared with the control reperfusion group. When we increased pH of the reperfused myocardium by an intracoronary infusion of sodium bicarbonate, beneficial effects of the staged reperfusion were abolished. Furthermore, an intracoronary infusion of hydrogen chloride, which mimicked the changes in pH in coronary venous blood of the staged reperfusion, attenuated myocardial stunning.
CONCLUSIONS: These results indicate that acidosis during staged reperfusion primarily attenuates myocardial stunning. This procedure is clinically applicable for attenuation of reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657451     DOI: 10.1161/01.cir.84.5.2135

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  14 in total

1.  Reperfusion Injury: Idle Curiosity or Therapeutic Vector?

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997-01       Impact factor: 2.300

2.  Myocardial protection in cardiac surgery: a historical review from the beginning to the current topics.

Authors:  Hiroshi Yamamoto; Fumio Yamamoto
Journal:  Gen Thorac Cardiovasc Surg       Date:  2013-07-23

3.  Transfused older stored red blood cells improve the clinical course and outcome in a canine lethal hemorrhage and reperfusion model.

Authors:  Steven B Solomon; Irene Cortés-Puch; Junfeng Sun; Kenneth E Remy; Dong Wang; Jing Feng; Sameena S Khan; Derek Sinchar; Daniel B Kim-Shapiro; Harvey G Klein; Charles Natanson
Journal:  Transfusion       Date:  2015-07-15       Impact factor: 3.157

4.  Preconditioning rabbit cardiomyocytes: role of pH, vacuolar proton ATPase, and apoptosis.

Authors:  R A Gottlieb; D L Gruol; J Y Zhu; R L Engler
Journal:  J Clin Invest       Date:  1996-05-15       Impact factor: 14.808

Review 5.  Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction.

Authors:  Kai Zacharowski; Paula Zacharowski; Sonja Reingruber; Peter Petzelbauer
Journal:  J Mol Med (Berl)       Date:  2006-05-06       Impact factor: 4.599

6.  Stuttering Reperfusion of Ischemic Myocardium Does Not Exacerbate Myocardial Infarction: Evidence Against Lethal Cell Reperfusion Injury in the Rabbit.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

7.  Effects of nicorandil on cardiac sympathetic nerve activity after reperfusion therapy in patients with first anterior acute myocardial infarction.

Authors:  Shu Kasama; Takuji Toyama; Hisao Kumakura; Yoshiaki Takayama; Shuichi Ichikawa; Tadashi Suzuki; Masahiko Kurabayashi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-10-02       Impact factor: 9.236

8.  Protection of the ischemic myocardium during the reperfusion: between hope and reality.

Authors:  Jean Chrisostome Bopassa
Journal:  Am J Cardiovasc Dis       Date:  2012-07-25

9.  Limitation of infarct size with preconditioning and calcium antagonist (diltiazem): difference in 99mTc-PYP uptake in the myocardium.

Authors:  K Okuda; R Nohara; M Ogino; N Tamaki; J Konishi; M Fujita; S Sasayama
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 10.  Controlling Reperfusion Injury With Controlled Reperfusion: Historical Perspectives and New Paradigms.

Authors:  Demetria M Fischesser; Bin Bo; Rachel P Benton; Haili Su; Newsha Jahanpanah; Kevin J Haworth
Journal:  J Cardiovasc Pharmacol Ther       Date:  2021-09-17       Impact factor: 2.457

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.